BNTX - Sorrento Therapeutics: More Than Just A Therapy For Those Who Don't Want To Be Stabbed With A Needle
- Sorrento is more than just a clinical stage biopharma company developing treatments for COVID, cancer and neurodegenerative diseases.
- It also generates revenues through contract manufacturing and sales of ZTlido used to treat Postherpetic Neuralgia.
- However, despite some remarkable therapies including using nasal drops, it is behind in the COVID-fighting race, with considerable volatility in its share price.
- Still, with a fairly strong balance sheet and a diversified pipeline into many life-saving treatments, the company is a buy.
- Going by the book, the company looks overvalued, but in the current variant-led infection scenario, its library of antibody sequences is considerably undervalued.
For further details see:
Sorrento Therapeutics: More Than Just A Therapy For Those Who Don't Want To Be Stabbed With A Needle